A5049458198- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Liver Disease Diagnosis and Treatment
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Biomedical Ethics and Regulation
- Glioma Diagnosis and Treatment
- Ethics in Clinical Research
- RNA modifications and cancer
- Renal cell carcinoma treatment
- RNA and protein synthesis mechanisms
Eli Lilly (United States)
2014-2023
Research Network (United States)
2009
Roswell Park Comprehensive Cancer Center
2009
Institute of Cytochemistry and Molecular Pharmacology
2006-2007
University of Louisville
2001
Abstract AGRO100, also known as AS1411, is an experimental anticancer drug that recently entered human clinical trials. It a member of novel class antiproliferative agents G-rich oligonucleotides (GRO), which are non-antisense, guanosine-rich phosphodiester oligodeoxynucleotides form stable G-quadruplex structures. The biological activity GROs results from their binding to specific cellular proteins aptamers. One important target protein has been previously identified nucleolin,...
Abstract AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. It currently in clinical trials as treatment for various cancers. We have proposed inhibits cancer cell proliferation by affecting the activities of certain nucleolin-containing complexes. Here, we report protein arginine methyltransferase 5 (PRMT5), an enzyme catalyzes formation symmetrical dimethylarginine (sDMA), nucleolin-associated whose localization and activity are altered AS1411. Levels PRMT5 were...
The discovery of G-rich oligonucleotides (GROs) that have non-antisense antiproliferative activity against a number cancer cell lines has been recently described. This biological GROs was found to be associated with their ability form stable G-quartet-containing structures and binding specific cellular protein, most likely nucleolin (Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, O., Miller, D. M. (1999) Biol. Chem. 274, 26369-26377). In this report, we further investigate the novel...
Abstract Purpose: Overactivation of TGF-β signaling is observed in myelodysplastic syndromes (MDS) and associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor the receptor type 1 kinase (ALK5) has shown effectiveness preclinical models MDS acceptable toxicity phase I studies solid malignancies. Patients Methods: A II multicenter study galunisertib was conducted patients very low-, or intermediate-risk by Revised International Prognostic Scoring...
477 Background: We assessed RAM or MER plus standard of care GEM+CIS as first-line treatment for BTC. Methods: Patients (pts) with BTC, ECOG PS 0/1, and measurable disease were randomized 2:1:2:1 to oral 80 mg QD, PL IV 8 mg/kg days 1 Q3W Q3W. Pts also received up cycles GEM 1000 mg/m 2 + CIS 25 RAM, MER, could continue until progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints: overall (OS), objective response rate (ORR), safety. PFS hazard ratios (HRs)...
BackgroundSymptoms of advanced hepatocellular carcinoma (HCC) represent a substantial burden for the patient and are important endpoints to assess when evaluating treatment. Patient-reported outcomes were evaluated in subjects with HCC baseline alpha-fetoprotein (AFP) ≥400 ng/mL treated second-line ramucirumab.Patients methodsPatients AFP≥400 enrolled REACH or REACH-2 phase 3 studies used this analysis. Eligible patients had HCC, Child-Pugh A, Eastern Cooperative Oncology Group performance...
Background: Glioblastoma (GB) treatment remains challenging because of recurrence and poorly defined options after first-line therapy. To better understand real-world application paradigms their impact on outcomes, we describe patterns treatment, use cancer-related healthcare resource for glioblastoma in the USA.
Evidence from randomized controlled trials available for timely health technology assessments of new pharmacological treatments and regulatory decision making may not be generalizable to local patient populations, often resulting in decisions being made under uncertainty. In recent years, several reweighting approaches have been explored address this important question generalizability a target population. We present case study the Innovative Medicines Initiative illustrate inverse...
Introduction: Cost considerations are increasingly becoming important in the care of patients with HCC, and may influence treatment decision making. The objective this study was to describe patterns evaluate direct medical costs HCC third-party payers. Methods: This retrospective cohort analyzed de-identified data from Truven MarketScan database, which contains longitudinal claims more than 175 million USA. Patients aged 18 or older, initially diagnosed (identified by ICD-9 ICD-10 codes)...
Historically, high hepatocellular carcinoma (HCC)-related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab. These two treatments utilize different routes administration (four daily tablets biweekly intravenous infusions, respectively) risks adverse events (AEs). However, we data on patient preferences balancing the route risk AEs patients with HCC. We aimed...
Aim: To investigate the association of discordance in patient- and physician-reported symptoms on health-related quality life (HRQoL) hepatocellular carcinoma (HCC). Patients & methods: Data were drawn from a point-in-time survey physicians patients conducted Germany, Italy Spain (October 2018 – January 2019). Physicians their consulting independently reported baseline characteristics, symptoms, treatment history satisfaction, HRQoL derived using Functional Assessment Cancer...
Although the demonstration of improved patient and clinical outcomes within randomized controlled trials (RCTs) is widely accepted as foundational evidence efficacy new treatments, concerns are frequently expressed that RCTs lack external validity. GetReal, a project under umbrella Innovation in Medicine Initiative, exploring how “real-life” data can be brought earlier drug development. We describe case study considers lung cancer most common worldwide. It investigates generalizability...
4077 Background: REACH did not demonstrate a significant improvement in overall survival (OS) the ITT population, but pts RAM group with an elevated baseline alpha-fetoprotein (AFP) ≥400ng/mL (pre-specified) had meaningful OS (HR 0.67, p < 0.05). Here we present PFOs (pt-reported FACT Hepatobiliary Symptom Indexes [FHSI-8] and clinician-reported Eastern Cooperative Oncology Group [ECOG] performance status [PS]) from study. Methods: Eligible advanced HCC; Child-Pugh A; ECOG PS 0 or 1; prior...